Coalition urges US Congress to repeal $20 billion medical device tax
This article was originally published in RAJ Devices
A broad coalition of US medical technology companies and industry associations is urging Congress to repeal the $20 billion medical device tax that is set to come into effect in 20131.
You may also be interested in...
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated to include two new products, including Alnylam Pharmaceuticals' Givlaari for treating acute hepatic porphyria. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.